NVAX (Novavax Inc) Stock Analysis - Analyst Ratings

Novavax Inc (NVAX) is a publicly traded Healthcare sector company. As of May 20, 2026, NVAX trades at $9.30 with a market cap of $1.47B and a P/E ratio of -17.12. NVAX moved +4.33% today. Year to date, NVAX is +27.86%; over the trailing twelve months it is +20.70%. Its 52-week range spans $5.01 to $15.22. Analyst consensus is neutral with an average price target of $11.60. Rallies surfaces NVAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate NVAX?

5 analysts cover NVAX: 0 strong buy, 2 buy, 1 hold, 2 sell, and 0 strong sell. The consensus rating is neutral. The average price target is $11.60.

NVAX Key Metrics

Key financial metrics for NVAX
MetricValue
Price$9.30
Market Cap$1.47B
P/E Ratio-17.12
EPS$-0.54
Dividend Yield0.11%
52-Week High$15.22
52-Week Low$5.01
Volume4.37M
Avg Volume0
Revenue (TTM)$596.34M
Net Income$-87.83M
Gross Margin84.97%

NVAX Analyst Consensus

5 analysts cover NVAX: 0 strong buy, 2 buy, 1 hold, 2 sell, 0 strong sell. Consensus rating is neutral. Average price target: $11.60.

Latest NVAX News

Common questions about NVAX

What do analysts rate NVAX?
5 analysts cover NVAX: 0 strong buy, 2 buy, 1 hold, 2 sell, and 0 strong sell. The consensus rating is neutral. The average price target is $11.60.
Does Rallies show NVAX price targets?
Yes. Rallies tracks NVAX analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is NVAX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for NVAX. It does not provide personalized investment advice.
NVAX

NVAX